Anteris Technologies Global Corp. (AVR)

Market Cap	195.61M
Revenue (ttm)	2.70M
Net Income (ttm)	-76.29M
Shares Out	36.02M
EPS (ttm)	-3.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,689
Open	4.965
Previous Close	5.120
Day's Range	4.550 - 5.060
52-Week Range	4.560 - 8.790
Beta	0.74
Analysts	Strong Buy
Price Target	16.50 (+236.05%)
Earnings Date	May 16, 2025

About AVR

Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaf...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 13, 2024
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: AVR
• Website: https://anteristech.com

Financial Performance

In 2024, AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for AVR stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 236.05% from the latest price.

Price Target

$16.5

(236.05% upside)

Analyst Consensus: Strong Buy